--- title: "Prelude Therapeutics (PRLD) stock: news and investor profile" url: "https://aibio.space/companies/prelude-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Prelude Therapeutics Incorporated (NASDAQ: PRLD), United States. The directory classifies it as Biotechnology." --- PRLD Prelude Therapeutics Incorporated NASDAQ · United States # Prelude Therapeutics (PRLD) news Financings · 2025-11-04 ## [Prelude Therapeutics signs Incyte option deal, to get $35 million cash and $25 million stock sale](https://aibio.space/news/prelude-therapeutics-signs-incyte-option-deal-get-35-million-cash-25/) Prelude Therapeutics gave Incyte an option on its preclinical JAK2V617F JH2 inhibitor program for a $35 million cash payment, plus a $25 million stock purchase. Exercising the option would cost Incyte $100 million, and the company is pausing a separate SMARCA2 degrader program. ## Latest Prelude Therapeutics news 1. 2025-09-19 Listings [Prelude Therapeutics regains compliance with Nasdaq $1.00 minimum bid price rule](https://aibio.space/news/prelude-therapeutics-regains-compliance-nasdaq-1-00-minimum-bid-price/) Nasdaq told Prelude on September 18, 2025 that the bid-price matter is closed. The company had been out of compliance since a March 27, 2025 notice. ## Prelude Therapeutics at a glance - **Ticker**: PRLD - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $151.8 million ### Related companies - [Q32 Bio](https://aibio.space/companies/q32-bio/) NASDAQ: QTTB - [AVVAA World Health Care Products](https://aibio.space/companies/avvaa-world-health-care-products/) OTC: AVVH - [FibroBiologics](https://aibio.space/companies/fibrobiologics/) NASDAQ: FBLG - [60 Degrees Pharmaceuticals](https://aibio.space/companies/60-degrees-pharmaceuticals/) NASDAQ: SXTP - [InVitro International](https://aibio.space/companies/invitro-international/) OTC: IVRO - [Recursion Pharmaceuticals](https://aibio.space/companies/recursion-pharmaceuticals/) NASDAQ: RXRX - [BioCryst Pharmaceuticals](https://aibio.space/companies/biocryst-pharmaceuticals/) NASDAQ: BCRX - [GRI Bio](https://aibio.space/companies/gri-bio/) NASDAQ: GRI ### Also on NASDAQ - [Instil Bio](https://aibio.space/companies/instil-bio/) TIL - [Immunic](https://aibio.space/companies/immunic/) IMUX - [Retension Pharmaceuticals](https://aibio.space/companies/retension-pharmaceuticals/) RTSN - [Sanara MedTech](https://aibio.space/companies/sanara-medtech/) SMTI - [CytomX Therapeutics](https://aibio.space/companies/cytomx-therapeutics/) CTMX - [Greenland Mines](https://aibio.space/companies/greenland-mines/) GRML ## What Prelude Therapeutics does Prelude Therapeutics Incorporated is a precision oncology company that discovers and develops novel precision cancer medicines for underserved patients. It creates new chemical entities against clinically validated targets in areas of high unmet need, using modalities such as targeted protein degradation. Its pipeline includes kinase programs, targeted protein degraders and precision antibody drug conjugates. Since its inception in 2016, the company says it has received clearance from the FDA for multiple investigational new drug applications and has advanced several programs into clinical trials. It works with partner AbCellera Biologics, Inc. on an early-stage discovery program involving potent degraders as payloads for novel antibodies that target tumor specific antigens. The company also has other proprietary programs in various stages of preclinical development. Its approach focuses on molecules with broad mechanisms that have multiple links to oncogenic driver pathways in select patients, with the aim of serving patients who have limited or no treatment options. | Product or program | What it is | Stage | |---|---|---| | Degrader payloads with AbCellera | Potent degraders as payloads for antibodies against tumor-specific antigens | early-stage discovery | | Kinase programs | Precision oncology kinase programs in the pipeline | | | Precision antibody drug conjugates | Antibody drug conjugate programs in the pipeline | | Summarised from the company's [10-K filed Mar 10, 2026](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/prld-20251231.htm). ## Prelude Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$12.1 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/) | [$7.0 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/) | | Research and development | [$94.3 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/) | [$118.0 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/) | | Net income (loss) | [-$99.5 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/) | [-$127.2 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/) | | Cash from operations | [-$56.3 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/) | [-$102.9 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/) | | Cash and equivalents | [$35.3 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526343475/) | [$12.5 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/) | | Short-term investments | [$68.0 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526343475/) | [$121.1 million](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $26.3 million, plus short-term investments of $125.4 million, $151.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Prelude Therapeutics What is the ticker symbol of Prelude Therapeutics? Prelude Therapeutics Incorporated trades under the ticker PRLD on NASDAQ. Where is Prelude Therapeutics listed? Prelude Therapeutics Incorporated is listed on NASDAQ. What is the SEC CIK of Prelude Therapeutics? The SEC Central Index Key (CIK) for Prelude Therapeutics Incorporated is 1678660. Its filings are on SEC EDGAR. How many shares does Prelude Therapeutics have outstanding? 79,803,485 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Prelude Therapeutics listed under? Our directory records Prelude Therapeutics Incorporated under United States. What does Prelude Therapeutics do? Our directory classifies Prelude Therapeutics Incorporated as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Prelude Therapeutics? The ISIN recorded for Prelude Therapeutics Incorporated is US74065P1012. Does aibio.space cover Prelude Therapeutics? aibio.space lists Prelude Therapeutics Incorporated among 2,820 public biotech companies and publishes its news here as stories appear. Where is Prelude Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Prelude Therapeutics develop? Prelude Therapeutics Incorporated is a precision oncology company that discovers and develops novel precision cancer medicines for underserved patients. It creates new chemical entities against clinically validated targets in areas of high unmet need, using modalities such as targeted protein degradation. What is Degrader payloads with AbCellera from Prelude Therapeutics? Degrader payloads with AbCellera: Potent degraders as payloads for antibodies against tumor-specific antigens Stage: early-stage discovery. What is Kinase programs from Prelude Therapeutics? Kinase programs: Precision oncology kinase programs in the pipeline Stage: not stated in text. What was Prelude Therapeutics's revenue last year? $12.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Prelude Therapeutics profitable? Prelude Therapeutics Incorporated reported a net loss of $99.5 million for the fiscal year ended Dec 31, 2025, and used $56.3 million of cash in operations, per its annual report to the SEC. How much does Prelude Therapeutics spend on research and development? $94.3 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Prelude Therapeutics Members talk about Prelude Therapeutics (PRLD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Prelude Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-04-21 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1678660/000119312526164486/d13255d424b5.htm) 2. 2026-03-12 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1678660/000119312526104185/d101590d424b5.htm) 3. 2025-11-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1678660/000092963825004115/exhibit99-1.htm) 4. 2025-09-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1678660/000119312525208187/prld-20250918.htm) 5. 2025-06-13 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07). [Source](https://www.sec.gov/Archives/edgar/data/1678660/000095017025086170/prld-20250611.htm) 6. 2025-05-06 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1678660/000095017025064566/prld-20250331.htm) 7. 2025-03-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1678660/000095017025046839/prld-20250327.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PRLD on TradingView](https://www.tradingview.com/symbols/NASDAQ-PRLD/). ## SEC filings and registration - **SEC name**: Prelude Therapeutics Inc - **CIK**: 1678660 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PRLD (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805 - **Phone**: (302) 467-1280 - **Shares outstanding**: 79,803,485 as of 2026-08-06 (10-Q filed 2026-08-11) - **Former names**: Prelude Therapeutics Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/prld-20260910.htm) filed 2026-09-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1678660/000119312526343475/prld-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1678660/000119312526343469/prld-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/prld-20260609.htm) filed 2026-06-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1678660/000119312526218173/prld-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/prld-20260512.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1678660/000119312526191532/prld-20260429.htm) filed 2026-04-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1678660/000119312526164510/d131537d8k.htm) filed 2026-04-21 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001678660), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Prelude Therapeutics Incorporated is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PRLD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Prelude Therapeutics Incorporated - **Ticker**: PRLD - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US74065P1012 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PRLD/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/prelude-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Prelude Therapeutics (PRLD) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/prelude-therapeutics/